


WHAT IS CLAIMED IS:

1. A compound represented by Formula I:



- wherein R^1 and R^2 are independently chosen from hydrogen or an alkyl group;
- 5 R^3 and R^4 are independently hydrogen or an alkyl group or;
 R^3 and R^4 and the carbon atom to which they are attached form a cycloalkyl ring, or;
 R^2 and R^3 together form a saturated $(CH_2)_m$ heterocycle;
 R^5 is hydrogen, halogen, or a substituted or unsubstituted alkyl group;
 R^6 and R^7 are independently hydrogen, halogen, cyano, an alkylthio, or a substituted or
10 unsubstituted alkyl group;
 R^8 and R^9 are independently hydrogen, hydroxyl, a substituted or unsubstituted alkyl
group, an alkoxy, $=O$, $NR^{10}R^{11}$, $OC(=O)NR^1R^2$, $OC(=O)C_{1-4}alkyl$, or an alkylthiol;
 R^{10} and R^{11} are independently hydrogen, a substituted or unsubstituted alkyl group,
 $C(=O)C_{1-4}alkyl$, $C(=O)OC_{1-4}alkyl$, or $C(=O)NR^1R^2$ or R^{10} and R^{11} together complete a
15 saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional
heteroatom selected from N, O, or S when a 6-membered ring;
A is $(CH_2)_n$, $C=O$, or $CHC_{1-4}alkyl$;
B is either a single or a double bond, wherein when B is a double bond, R^8 and R^9 are
selected from hydrogen, or a substituted or unsubstituted alkyl group;
- 20 $m = 2-4$;
 $n = 0-2$;
X and Y are either N or C, wherein X and Y are different; and the dashed bonds denote a
suitably appointed single and double bond.

2. The compound of claim 1, wherein R^2 and R^3 form a saturated $(CH_2)_m$ heterocycle.

3. The compound of claim 1, wherein said R^3 and R^4 together form a cyclopropyl ring.

5 4. The compound of claim 1, wherein R^1 and R^2 are independently chosen from hydrogen or C_{1-4} alkyl;

R^3 and R^4 are independently chosen from hydrogen or C_{1-4} alkyl, or R^2 and R^3 together form a saturated $(CH_2)_m$ heterocycle;

R^5 is chosen from hydrogen, halogen, or C_{1-6} alkyl;

10 R^6 and R^7 are independently chosen from hydrogen, halogen, cyano, C_{1-4} alkylthio, C_{1-4} alkyl, or C_{1-4} alkyl substituted by halogen;

R^8 and R^9 are chosen from hydrogen, hydroxyl, C_{1-6} alkyl, C_{1-6} alkoxy, $NR^{10}R^{11}$, or C_{1-6} alkyl substituted with halogen, hydroxyl, or $NR^{10}R^{11}$;

R^{10} and R^{11} are independently chosen from hydrogen or C_{1-4} alkyl or $C(=O)C_{1-4}$ alkyl or R^{10} and R^{11} together complete a saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is $(CH_2)_n$ or CHC_{1-4} alkyl;

B is either a single or double bond, wherein when B is a double bond, R^8 and R^9 are selected from hydrogen, C_{1-4} alkyl, or C_{1-4} alkyl substituted by halogen, hydroxy, or $NR^{10}R^{11}$;

$m = 3-4$;

$n = 1-2$; and

X and Y are either N or C, wherein X and Y cannot be the same; and
25 the dashed bonds denote a suitably appointed single and double bond.

5. The compound of claim 1, wherein R¹ and R² are independently chosen from hydrogen or C₁₋₄alkyl;
- R³ is C₁₋₂alkyl, or R² and R³ together are (CH₂)₃ to form pyrrolidine;
- R⁴ is hydrogen;
- 5 R⁵ is chosen from hydrogen or C₁₋₆alkyl;
- R⁶ and R⁷ are independently chosen from hydrogen, halogen, or C₁₋₄alkyl;
- R⁸ and R⁹ are independently chosen from hydrogen, hydroxyl, C₁₋₆alkoxy, NR¹⁰R¹¹, or C₁₋₆alkyl substituted with hydroxyl or NR¹⁰R¹¹;
- R¹⁰ and R¹¹ are independently chosen from hydrogen, C₁₋₄alkyl or C(=O)C₁₋₄alkyl
- 10 or R¹⁰ and R¹¹ together complete a saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional heteroatom selected from N, O, or S when a 6-membered ring;
- A is (CH₂)_n;
- B is a single bond;
- 15 n = 1;
- X is C and Y is N; and
- the dashed bonds denote a suitably appointed single and double bond.
6. The compound of claim 1, wherein said compound is:
- 1-(2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;
- 20 1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;
- (R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;
- (S)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;
- 1-((S)-2-Aminopropyl)-3-methyl-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;
- 1-(S)-1-Pyrrolidin-2-ylmethyl-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;
- 25 1-((S)-2-Aminopropyl)-5-fluoro-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;

- (R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ylamine;
[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-yl]-dimethylamine;
[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-yl]-methanol;
1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazole-8,9-diol;
5 1-((S)-2-Aminopropyl)-9-methoxy-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;
1-(2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;
1-(Pyrrolidin-2-ylmethyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;
1-((S)-2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol;
1-((S)-2-Aminopropyl)-3-methyl-3,7,8,9-tetrahydro-pyrano[3,2-*e*]indazol-8-ol; or
10 combinations thereof.
7. The compound of claim 1, wherein said X is N.
8. The compound of claim 1, wherein said X is C.
9. A method of controlling normal or elevated intraocular pressure comprising
administering a pharmaceutically effective amount of a composition comprising at least one
15 compound of claim 1.
10. The method of claim 9, wherein R^2 and R^3 form a saturated $(CH_2)_m$
heterocycle.
11. The method of claim 9, wherein said R^3 and R^4 together form a cyclopropyl
ring.
- 20 12. The method of claim 9, wherein R^1 and R^2 are independently chosen from
hydrogen or C_{1-4} alkyl;
 R^3 and R^4 are independently chosen from hydrogen or C_{1-4} alkyl, or R^2 and R^3
together form a saturated $(CH_2)_m$ heterocycle;
 R^5 is chosen from hydrogen, halogen, or C_{1-6} alkyl;

R^6 and R^7 are independently chosen from hydrogen, halogen, cyano, C_{1-4} alkylthio, C_{1-4} alkyl, or C_{1-4} alkyl substituted by halogen;

R^8 and R^9 are chosen from hydrogen, hydroxyl, C_{1-6} alkyl, C_{1-6} alkoxy, $NR^{10}R^{11}$, or C_{1-6} alkyl substituted with halogen, hydroxyl, or $NR^{10}R^{11}$;

5 R^{10} and R^{11} are independently chosen from hydrogen or C_{1-4} alkyl or $C(=O)C_{1-4}$ alkyl or R^{10} and R^{11} together can complete a saturated 5 or 6-membered heterocyclic ring, which can include an additional heteroatom selected from N, O, or S when a 6-membered ring;

A is $(CH_2)_n$ or CHC_{1-4} alkyl;

10 B is either a single or double bond, wherein when B is a double bond, R^8 and R^9 are selected from hydrogen, C_{1-4} alkyl, or C_{1-4} alkyl substituted by halogen, hydroxy, or $NR^{10}R^{11}$;

$m = 3-4$;

$n = 1-2$; and

15 X and Y are either N or C, wherein X and Y cannot be the same; and

the dashed bonds denote a suitably appointed single and double bond.

13. The method of claim 9, wherein R^1 and R^2 are independently chosen from hydrogen or C_{1-4} alkyl;

R^3 is C_{1-2} alkyl, or R^2 and R^3 together are $(CH_2)_3$ to form pyrrolidine;

20 R^4 is hydrogen;

R^5 is chosen from hydrogen or C_{1-6} alkyl;

R^6 and R^7 are independently chosen from hydrogen, halogen, or C_{1-4} alkyl;

R^8 and R^9 are independently chosen from hydrogen, hydroxyl, C_{1-6} alkoxy, $NR^{10}R^{11}$, or C_{1-6} alkyl substituted with hydroxyl or $NR^{10}R^{11}$;

R^{10} and R^{11} are independently chosen from hydrogen, C_{1-4} alkyl or $C(=O)C_{1-4}$ alkyl or R^{10} and R^{11} together complete a saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional heteroatom selected from N, O, or S when a 6-membered ring;

5 A is $(CH_2)_n$;

B is a single bond;

n = 1;

X is C and Y is N; and

the dashed bonds denote a suitably appointed single and double bond.

10 14. The method of claim 9, wherein said compound is:

1-(2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;

1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;

(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;

(S)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;

15 1-((S)-2-Aminopropyl)-3-methyl-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;

1-(S)-1-Pyrrolidin-2-ylmethyl-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;

1-((S)-2-Aminopropyl)-5-fluoro-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;

(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ylamine;

[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-yl]-dimethylamine;

20 [1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-yl]-methanol;

1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazole-8,9-diol;

1-((S)-2-Aminopropyl)-9-methoxy-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;

1-(2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol;

1-(Pyrrolidin-2-ylmethyl)-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol;

25 1-((S)-2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol;

1-((S)-2-Aminopropyl)-3-methyl-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol; or combinations thereof.

15. The method of claim 9, wherein said X is N.

16. The method of claim 9, wherein said X is C.

5 17. A method for the treatment of glaucoma comprising administering a pharmaceutically effective amount of a composition comprising at least one compound of claim 1.

18. The method of claim 17, wherein R^1 and R^2 are independently chosen from hydrogen or C_{1-4} alkyl;

10 R^3 and R^4 are independently chosen from hydrogen or C_{1-4} alkyl, or R^2 and R^3 together form a saturated $(CH_2)_m$ heterocycle;

R^5 is chosen from hydrogen, halogen, or C_{1-6} alkyl;

R^6 and R^7 are independently chosen from hydrogen, halogen, cyano, C_{1-4} alkylthio, C_{1-4} alkyl, or C_{1-4} alkyl substituted by halogen;

15 R^8 and R^9 are chosen from hydrogen, hydroxyl, C_{1-6} alkyl, C_{1-6} alkoxy, $NR^{10}R^{11}$, or C_{1-6} alkyl substituted with halogen, hydroxyl, or $NR^{10}R^{11}$;

R^{10} and R^{11} are independently chosen from hydrogen or C_{1-4} alkyl or $C(=O)C_{1-4}$ alkyl or R^{10} and R^{11} together can complete a saturated 5 or 6-membered heterocyclic ring, which can include an additional heteroatom selected from N, O, or S when a 6-membered
20 ring;

A is $(CH_2)_n$ or CHC_{1-4} alkyl;

B is either a single or double bond, wherein when B is a double bond, R^8 and R^9 are selected from hydrogen, C_{1-4} alkyl, or C_{1-4} alkyl substituted by halogen, hydroxy, or $NR^{10}R^{11}$;

25 $m = 3-4$;

n = 1-2; and

X and Y are either N or C, wherein X and Y cannot be the same; and

the dashed bonds denote a suitably appointed single and double bond.

19. The method of claim 17, wherein R¹ and R² are independently chosen from
5 hydrogen or C₁₋₄alkyl;

R³ is C₁₋₂alkyl, or R² and R³ together are (CH₂)₃ to form pyrrolidine;

R⁴ is hydrogen;

R⁵ is chosen from hydrogen or C₁₋₆alkyl;

R⁶ and R⁷ are independently chosen from hydrogen, halogen, or C₁₋₄alkyl;

10 R⁸ and R⁹ are independently chosen from hydrogen, hydroxyl, C₁₋₆alkoxy,
NR¹⁰R¹¹, or C₁₋₆alkyl substituted with hydroxyl or NR¹⁰R¹¹;

R¹⁰ and R¹¹ are independently chosen from hydrogen, C₁₋₄alkyl or C(=O)C₁₋₄alkyl
or R¹⁰ and R¹¹ together complete a saturated 5 or 6-membered heterocyclic ring, which
optionally includes an additional heteroatom selected from N, O, or S when a 6-membered
15 ring;

A is (CH₂)_n;

B is a single bond;

n = 1;

X is C and Y is N; and

20 the dashed bonds denote a suitably appointed single and double bond.

20. The method of claim 17, wherein said compound is:

1-(2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;

1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;

(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;

25 (S)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;

- 1-((S)-2-Aminopropyl)-3-methyl-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;
1-(S)-1-Pyrrolidin-2-ylmethyl-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;
1-((S)-2-Aminopropyl)-5-fluoro-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;
(R)-1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ylamine;
5 [1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-yl]-dimethylamine;
[1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-yl]-methanol;
1-((S)-2-Aminopropyl)-1,7,8,9-tetrahydro-pyrano[2,3-g]indazole-8,9-diol;
1-((S)-2-Aminopropyl)-9-methoxy-1,7,8,9-tetrahydro-pyrano[2,3-g]indazol-8-ol;
1-(2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol;
10 1-(Pyrrolidin-2-ylmethyl)-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol;
1-((S)-2-Aminopropyl)-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol;
1-((S)-2-Aminopropyl)-3-methyl-3,7,8,9-tetrahydro-pyrano[3,2-e]indazol-8-ol; or
combinations thereof.

21. A pharmaceutical composition comprising the compound of claim 1 and at
15 least one carrier.

22. A method to block or bind to serotonin receptors comprising administering an
effective amount of at least one compound of claim 1 to a patient.